Clene insider ends control of 799,358 warrant shares
Clene Inc. insider Chidozie Ugwumba reported an internal restructuring on July 17, 2026, disposing of beneficial ownership of warrants over 799,358 Clene common shares that had been held indirectly through SymBiosis II LLC.
Rhea-AI Filing Summary
Clene Inc. insider Chidozie Ugwumba reported an internal restructuring on July 17, 2026, disposing of beneficial ownership of warrants over 799,358 Clene common shares that had been held indirectly through SymBiosis II LLC. Management of the fund’s portfolio shifted to an unaffiliated manager; no warrants were exercised, sold, transferred, or paid for, and Ugwumba ceased to be a ten percent owner subject to Section 16.
Positive
- None.
Negative
- None.
Insider Trade Summary
Other: 799,358 shares
Other
2 txns
Insider
Ugwumba Chidozie
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Warrant to Purchase Common Stock (Tranche B, $30.00 strike) F1, F3, F2 | 375,000 | -- | -- |
| Other | Common Stock Purchase Warrant ($4.82 strike) F1, F3, F2 | 424,358 | -- | -- |
Holdings After Transaction:
Warrant to Purchase Common Stock (Tranche B, $30.00 strike) — 0 contracts (Indirect, By SymBiosis II LLC);
Common Stock Purchase Warrant ($4.82 strike) — 0 contracts (Indirect, By SymBiosis II LLC)
Footnotes (3)
- F1. The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred.
- F2. Currently exercisable
- F3. The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received.
Key Figures
Tranche B warrant underlying shares: 375000.0000 shares
Tranche B warrant strike price: 30.0000 per share
Common Stock Purchase Warrant underlying shares: 424358.0000 shares
+4 more
7 metrics
Tranche B warrant underlying shares
375000.0000 shares
Warrant to Purchase Common Stock, $30.00 strike, indirect holding by SymBiosis II LLC
Tranche B warrant strike price
30.0000 per share
Conversion or exercise price for Tranche B Warrant to Purchase Common Stock
Common Stock Purchase Warrant underlying shares
424358.0000 shares
Common Stock Purchase Warrant, $4.82 strike, indirect holding by SymBiosis II LLC
Common Stock Purchase Warrant strike price
4.8200 per share
Conversion or exercise price for Common Stock Purchase Warrant
Warrant restructuring shares
799358 shares
Total underlying shares affected by restructuring transactions coded J on July 17, 2026
Tranche B warrant expiration
2030-06-16
Expiration date of Warrant to Purchase Common Stock (Tranche B, $30.00 strike)
Common Stock Purchase Warrant expiration
2029-09-30
Expiration date of Common Stock Purchase Warrant ($4.82 strike)
Key Terms
beneficially own, Section 16, Common Stock Purchase Warrant, ten percent owner
4 terms
beneficially own regulatory
"The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Section 16 regulatory
"no longer subject to the reporting requirements of Section 16 of the Securities Exchange Act"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Common Stock Purchase Warrant financial
"Common Stock Purchase Warrant ($4.82 strike)"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
ten percent owner regulatory
"as an owner of more than ten percent of any class of the Issuer's equity securities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Clene Inc. (CLNN) insider Chidozie Ugwumba report on this Form 4?
He reported that his beneficial ownership of warrants over 799,358 Clene common shares, held indirectly via SymBiosis II LLC, ended after portfolio management transferred to an unaffiliated manager. The filing notes no warrants were exercised, sold, transferred, or paid for.
Were any Clene Inc. (CLNN) securities sold or exercised in this Form 4?
No. Footnotes state that no warrants were exercised, sold, or transferred and no consideration was paid or received. The change reflects only a transfer of portfolio management and the resulting end of Ugwumba’s beneficial ownership of the fund’s warrant holdings.
Which Clene Inc. (CLNN) securities are involved and what are their strike prices?
The Form 4 covers a Tranche B Warrant for 375,000 underlying common shares at $30.00 per share and a Common Stock Purchase Warrant for 424,358 underlying common shares at $4.82 per share, all previously held indirectly through SymBiosis II LLC.
How does this Form 4 affect Ugwumba’s Section 16 status for Clene Inc. (CLNN)?
The filing states Ugwumba is no longer subject to Section 16 reporting for Clene because, after this restructuring, he no longer has a relationship as an owner of more than ten percent of any class of the company’s equity securities, ending his ten percent owner status.
What role did SymBiosis II LLC play in the Clene Inc. (CLNN) warrant holdings?
Ugwumba was deemed to beneficially own the warrants indirectly through SymBiosis II LLC due to voting and investment power over the fund’s holdings. Effective July 17, 2026, that power transferred to an unaffiliated manager, so he no longer beneficially owns the reported warrants.
Are the Clene Inc. (CLNN) warrants currently exercisable and when do they expire?
A footnote states the warrants are currently exercisable. The Tranche B Warrant for 375,000 shares at $30.00 per share expires on June 16, 2030, and the Common Stock Purchase Warrant for 424,358 shares at $4.82 per share expires on September 30, 2029.
AI-generated analysis. How Rhea-AI works. Not financial advice.
